This acquisition expands Endpoint into clinical supply planning while keeping Bluefin independent and RTSM-agnostic.

RALEIGH, N.C. and BOSTON, Sept. 14, 2026 /PRNewswire/ — Endpoint Clinical L.P., a global leader in randomization and trial supply management (“RTSM”) solutions and a portfolio company of Arsenal Capital Partners, today announced it has acquired Bluefin, a Boston-based provider of clinical supply forecasting and planning technology.

The acquisition expands Endpoint into clinical supply chain planning while keeping Bluefin focused on its core forecasting and planning mission. Bluefin will operate independently and continue to connect with RTSM systems across the industry. Endpoint will support Bluefin with global project management, implementation, quality, and customer support capabilities to help sponsors deploy the platform reliably and efficiently.

“Clinical supply planning is becoming more complex, more connected to trial execution, and more dependent on timely intelligence,” said Nagaraja “Sri” Srivatsan, Chief Executive Officer of Endpoint Clinical. “Bluefin gives Endpoint a strong foundation in clinical supply planning while preserving customer choice across RTSM providers. Together, we have the opportunity to bring intelligence into every aspect of clinical supply, connecting planning, forecasting, enrollment signals, inventory movement, and RTSM execution data so every sponsor can make faster, better-informed decisions across all their studies. Endpoint can also bring the implementation discipline and support needed to deploy these capabilities reliably at scale.”

Clinical supply teams have long recognized that better outcomes come from connecting supply plans to the data that trials generate in real time; the challenge has been bringing those data sources together in a way that supports timely, actionable decision-making. Endpoint and Bluefin are helping close that gap, linking supply plans to trial execution data so teams can anticipate enrollment shifts and automate forecasting rather than react to them. Bluefin will maintain its open, RTSM- and forecasting-agnostic model, which both companies see as core to advancing the industry.

“We’re thrilled to be joining the Endpoint team,” said Andy Maltun, Co-Founder and Chief Executive Officer of Bluefin. “The connection between RTSM and clinical supply forecasting is so natural that it’s one of the first opportunities we discuss with every sponsor. Together, we are building a clinical supply intelligence platform that uses modern technology to automate manual work, reduce risk, and lower cost through optimized supply plans.”

“This acquisition is consistent with our strategy of building technology-rich companies that solve meaningful enterprise problems for healthcare customers,” said Mark A. Goldberg, MD, Chairman of the Board of Directors of Endpoint Clinical and Operating Partner at Arsenal Capital Partners. “Endpoint gains a path into clinical supply planning, Bluefin gains resources to scale, and the market continues to benefit from an independent planning platform that works across any RTSM environment.” Arsenal acquired Endpoint Clinical in 2024 and continues to support the company’s growth and evolution of its RTSM platforms and AI capabilities.

By bringing clinical supply planning closer to real-time trial execution, Endpoint and Bluefin aim to give sponsors greater intelligence and confidence in managing increasingly complex global studies.

For more information, visit Endpoint Clinical and Bluefin.

About Endpoint Clinical

Endpoint Clinical is a trusted clinical trial technology and service partner that delivers reliable RTSM solutions. Endpoint blends seamlessly into clinical trial processes by providing anticipatory and adaptive solutions to proactively mitigate risks. With decades of experience, Endpoint offers a deep understanding of the challenges that sponsors and CROs face. Its tech-forward dedication to innovation and high-touch services enable Endpoint to control the controllables and proactively generate speedy, strategic solutions, so sponsors and CROs can focus on running seamless clinical trials.

About Bluefin

Bluefin is a clinical supply forecasting and planning technology company focused on helping sponsors and CROs make smarter, data-driven supply decisions. Its platform enables organizations to forecast demand, evaluate supply scenarios, optimize distribution strategies, and proactively manage supply risk across the clinical trial lifecycle. Through advanced modeling and planning capabilities, Bluefin helps clinical supply teams improve visibility, increase operational confidence, and support more efficient trial execution.

About Arsenal Capital Partners

Arsenal Capital Partners is a leading private equity investment firm that specializes in building market-leading industrial growth and healthcare companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds totaling more than $10 billion, completed more than 300 platform and add-on acquisitions, and achieved more than 35 realizations. The firm partners with management teams to build strategically important companies with leading market positions, high growth, and high value-add. For more information, visit www.arsenalcapital.com.

Media Contact

Isabella Buhman
ibuhman@endpointclinical.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/endpoint-clinical-acquires-bluefin-a-provider-of-clinical-supply-forecasting-and-planning-technology-302877573.html

SOURCE Endpoint Clinical